EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

Tomohiro Yabushita, Takumi Chinen, Atsuya Nishiyama, Shuhei Asada, Ruka Shimura, Tomoya Isobe, Keita Yamamoto, Naru Sato, Yutaka Enomoto, Yosuke Tanaka, Tomofusa Fukuyama, Hitoshi Satoh und 10 weitere

Cell Reports · 2023

DOI: 10.1016/j.celrep.2023.113098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Tomohiro Yabushita und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Uehara Memorial Foundation, Core Research for Evolutional Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineLeukemia, Myeloid, AcuteHumansDecitabineAntimetabolites, AntineoplasticDNA MethylationDNAAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

ATRCHK1CP: CancerDNA hypomethylating agentDNA methylationDNMT1HMAcholesteroldecitabinemitosismitotic catastrophe

Substanzen

DecitabineAzacitidineAntimetabolites, AntineoplasticDNACLSPN protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Division of Cancer Cell Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; The Institute of Laboratory Animals, Tokyo Women's Medical University, Tokyo, Japan.
  • Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicin…

Förderung

  • Japan Agency for Medical Research and Development
  • Uehara Memorial Foundation
  • Core Research for Evolutional Science and Technology
  • Kanae Foundation for the Promotion of Medical Science
  • Japan Society for the Promotion of Science

Zitieren

APA

Yabushita, T., Chinen, T., Nishiyama, A., Asada, S., Shimura, R., Isobe, T., Yamamoto, K., Sato, N., Enomoto, Y., Tanaka, Y., Fukuyama, T., Satoh, H., Kato, K., Saitoh, K., Ishikawa, T., Soga, T., Nannya, Y., Fukagawa, T., Nakanishi, M., …, & Goyama, S. (2023). Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113098

Vancouver

Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, et al. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell Reports. 2023. doi:10.1016/j.celrep.2023.113098

BibTeX
@article{Yabushita2023,
  author = {Yabushita, Tomohiro and Chinen, Takumi and Nishiyama, Atsuya and Asada, Shuhei and Shimura, Ruka and Isobe, Tomoya and Yamamoto, Keita and Sato, Naru and Enomoto, Yutaka and Tanaka, Yosuke and Fukuyama, Tomofusa and Satoh, Hitoshi and Kato, Keiko and Saitoh, Kaori and Ishikawa, Takamasa and Soga, Tomoyoshi and Nannya, Yasuhito and Fukagawa, Tatsuo and Nakanishi, Makoto and Kitagawa, Daiju and Kitamura, Toshio and Goyama, Susumu},
  title = {Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment},
  journal = {Cell Reports},
  year = {2023},
  doi = {10.1016/j.celrep.2023.113098}
}
Kostenlos starten →